Publication: Outcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
1
0
Issued Date
2023
Resource Type
File Type
application/pdf
Rights Holder(s)
Scopus
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol 24, No.4 (2023), p.1401-1405
Suggested Citation
Hamontri S., Tantitamit T. Outcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer. Asian Pacific Journal of Cancer Prevention. Vol 24, No.4 (2023), p.1401-1405. doi:10.31557/APJCP.2023.24.4.1401 Retrieved from: https://hdl.handle.net/20.500.14740/9051
Author(s)
Other Contributor(s)
Abstract
Objective: To determine the survival outcomes and prognostic factors of the patients with recurrent platinumresistant and refractory epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Methods: Women with recurrent platinum-resistant and refractory EOC, tubal and peritoneal cancer who received treatment at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) between January 2010 and December 2019 were included. Demographic data, serum marker, surgical factors, pathological factors and response of treatment were reviewed. Kaplan-Meier was used to calculate survival outcome. Result: Forty patients were recruited in this study (platinum-resistant 24 patients and refractory 16 patients). The median survival times were 19 and 21 months in and platinum-resistant and platinumrefractory patients, respectively. There were no significant differences in overall survival according to age, comorbidity, tumor grading, primary treatment, and secondary surgery. However, histology of clear cell carcinoma may associate with increased risk of death. The median overall survival of patients with clear cell carcinoma, serous carcinoma, and others were 14.4, 22.9, and 32.2, respectively (p = 0.003). Conclusion: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License